No way! But... [Design Issues]

posted by wienui  – Germany, Oman, 2019-12-07 04:01 (727 d 08:00 ago) – Posting: # 20955
Views: 4,833

(edited by wienui on 2019-12-07 06:47)

Dear all,

» So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)

I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 10 (1 registered, 9 guests [including 7 identified bots]).
Forum time: Friday 12:01 CET (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5